Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 3/20 | 0.50 |
| ▸ | AAK1 | Q2M2I8 | 5/20 | 0.40 |
| ▸ | GAK | O14976 | 4/20 | 0.40 |
| ▸ | STK16 | O75716 | 4/20 | 0.40 |
| ▸ | BMP2K | Q9NSY1 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | PKM | P14618 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | TDP2 | O95551 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | RIOK3 | O14730 | 1/20 | 0.36 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.36 |
| ▸ | CDKL2 | Q92772 | 1/20 | 0.36 |
| ▸ | RIOK1 | Q9BRS2 | 1/20 | 0.36 |
| ▸ | MYLK2 | Q9H1R3 | 1/20 | 0.36 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL460549 | 0.67 | AAK1 (0.43) | GRIA2AAK1GAKSTK16BMP2K | |
| SCHEMBL2929244 | 0.67 | GRIA2 (1.00) | GRIA2 | |
| SCHEMBL460332 | 0.67 | AAK1 (0.45) | GRIA2AAK1BRD4KMT2AMEN1 | |
| SCHEMBL438630 | 0.65 | GRIA2 (0.53) | GRIA2AAK1PIP5K1C | |
| SCHEMBL10197667 | 0.65 | GRIA2 (0.53) | GRIA2AAK1ALDH1A1PIP5K1C | |
| SCHEMBL10197813 | 0.65 | DRD2 (0.39) | GRIA2KMT2AMEN1ABL1 | |
| SCHEMBL346350 | 0.65 | MAPK1 (0.48) | GRIA2AAK1ALDH1A1HTTKMT2A | |
| SCHEMBL2934347 | 0.65 | GRIA2 (0.83) | GRIA2 | |
| SCHEMBL460073 | 0.65 | HDAC1 (0.41) | GRIA2ALDH1A1 | |
| SCHEMBL461533 | 0.64 | JAK1 (0.35) | GRIA2ALDH1A1PKMHTTABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243334-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243334-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| WO-2012012320-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENIUM PHARMACEUTICALS, INC. (US) | 2012-01-26 | — | — | WO | disclosed |
| WO-2012012320-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENIUM PHARMACEUTICALS, INC. (US) | 2012-01-26 | — | — | WO | disclosed |
| US-20120015942-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120015942-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015942-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC2 | GRIA2 237/4885AAK1 4580/4885GAK 1902/4885 |
| US-20140243334-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | HDAC6, H1-3, H1-5 | GRIA2 674/4885AAK1 4555/4885GAK 2740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.